Form 4: Kamada Ltd. VP Reports Stock Option Transactions

Kamada Ltd. VP of Plasma Operations, Beladev Shavit, reported transactions involving employee stock options on April 7, 2026.

Summary

• Beladev Shavit, VP of Plasma Operations at Kamada Ltd. (KMDA), has reported transactions related to employee stock options.
• The transactions occurred on April 7, 2026, and involved multiple option grants with exercise prices ranging from $5.87 to $7.50.
• A total of 15,000 ordinary shares are associated with each option grant, with vesting occurring in four equal installments on the anniversaries of the grant date.
• The options are held by a trustee under the Company's 2011 Share Award Plan.
• Exercise prices were adjusted due to a cash dividend distribution declared by the board on March 11, 2026, as per the 2011 Share Award Plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It reports routine insider transactions related to stock options and does not contain new financial performance data or strategic shifts that would significantly alter the investment outlook.

Positives

• The reporting person, a key executive, is actively engaged with the company's equity through stock options.
• The stock options are part of a structured award plan, indicating a long-term incentive for management.
• Vesting schedules suggest a commitment to retaining talent and aligning executive interests with company performance over time.

Negatives

• The filing details transactions of options, not necessarily the exercise or sale of shares, so immediate financial impact is not detailed.
• The specific market value or current trading price of KMDA shares is not provided in this filing, making it difficult to assess the immediate value of these options.

Risks

• The value of the reported stock options is directly tied to the future performance and stock price of Kamada Ltd., which carries inherent market risks.
• Changes in the company's stock price could render some or all of these options less valuable or worthless.
• The adjustment of exercise prices due to dividends, while compliant with the plan, could be perceived differently by various stakeholders depending on the magnitude of the dividend and its impact on share value.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions related to stock options.

Management Comments

• The exercise price of the options was adjusted pursuant to the provisions of the Company's 2011 Share Award Plan in connection with a cash dividend distribution declared by the Company's board of directors on March 11, 2026. There are no other changes to the terms and conditions of the option award.
• Options vest in four equal installments, with 25% vesting on each of the four anniversaries of the date of grant.
• Held by trustee under the Company's 2011 Share Award Plan.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard for reporting changes in beneficial ownership by insiders, including executive stock option activity. This type of disclosure is common across the biotechnology and pharmaceutical sectors, where equity-based compensation is a key tool for attracting and retaining talent.

Stakeholder Impact

• Shareholders: This filing provides transparency into executive compensation and potential future share dilution if options are exercised. The adjustment of option prices due to dividends is a standard practice but could be a point of discussion regarding executive benefits.
• Employees: The existence of such stock option plans can be a positive motivator for other employees, signaling the company's commitment to rewarding performance.
• Management: The reporting person's continued engagement with company stock through options aligns their interests with long-term shareholder value.

Next Steps

• The options will continue to vest according to their respective schedules.
• The reporting person may exercise vested options in the future, subject to the terms of the plan and market conditions.

Key Dates

Keywords

Kamada Ltd., KMDA, Form 4, Stock Options, Beneficial Ownership, Insider Trading, Executive Compensation, SEC Filing, Beladev Shavit, Plasma Operations